Bayer
↗Leverkusen, Germany
Bayer is a global leader in the life sciences industry with operations spanning pharmaceuticals, crop science, and consumer health. The company operates with three major divisions: Pharmaceuticals (focused on oncology, cardiology, renal disease, neurology, rare disease, and immunology), Crop Science (agricultural chemicals and seeds), and Consumer Health (over-the-counter health products). With origins dating back to 1863 in Germany, Bayer has evolved into a multinational conglomerate with approximately 99,720 employees worldwide and generates annual revenues exceeding €45-47 billion (approximately $51 billion USD). The company completed the landmark acquisition of Monsanto in June 2018 for $63 billion, significantly expanding its crop science portfolio, though this acquisition has been followed by extensive litigation related to glyphosate-based herbicides.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Diversified Pharmaceutical, Agrochemical
SIZE & FINANCIALS
Employees:10000+
Revenue:$45B-$47B EUR annually (approximately $51B USD)
Founded:1863
Ownership:public
Status:operating
STOCK
Exchange:XETRA (Frankfurt Stock Exchange), NYSE, NASDAQ
Ticker:BAYN (XETRA), BAYRY (OTC/ADR)
Market Cap:$40.65B USD
PIPELINE
Stage:Discovery through Commercial
Lead Drug Stage:Phase 3 and Commercial
Modalities:Small molecule, mAb (monoclonal antibodies), Tyrosine kinase inhibitors, Cell therapy, Gene therapy, Biologics
Trial Phases:Phase 1: 55 | Phase 2: 39 | Phase 3: 14
FDA Approvals:94
CORPORATE STRUCTURE
Subsidiaries:Monsanto Company, Vividion (acquired Tavros Therapeutics Dec 2024)
Key Partnerships:WHO (renewed 2025-2030 collaboration for neglected tropical diseases), Purdue University (Coalition for Sustainable and Regenerative Agriculture, 2024), M2i Group (pheromone-based biological crop protection, global expansion 2025), Microsoft (Azure Data Manager for Agriculture, Bayer AgPowered Services), Aignostics GmbH (precision oncology targets), NextRNA Therapeutics (non-coding RNA targeting in oncology), Mammoth Biosciences (gene-editing technology), Suzhou Puhe BioPharma (oral PRMT5 inhibitor for MTAP-deleted tumors), TetraScience (scientific data management expansion), BridgeBio (transthyretin amyloid cardiomyopathy - acoramidis)
COMPETITION
Position:Leader
Competitors:Pfizer, AstraZeneca, Bristol Myers Squibb, Merck & Co, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Novartis +1 more
LEADERSHIP
Key Executives:
Bill Anderson - Chief Executive Officer & Chairman
Wolfgang Nickl - Chief Financial Officer
Dr. Judith Hartmann - Chief Financial Officer (incoming)
Sebastian Guth - Chief Operating Officer
Christine Roth - Head of Global Commercialization
Christian Rommel - Head of Research & Development
Holger Weintritt - Head of Product Supply
Scientific Founders:Friedrich Bayer, Johann Friedrich Weskott
Board Members:Norbert Winkeljohann (Supervisory Board Chairman)
LINKS
Website:bayer.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Bayer. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.